Evidence map›Paper›PMID 34661093›Full record

ArticleInternational journal of pharmaceutics: X2021

Towards a better understanding of thermally treated polycarbophil matrix tablets for controlled release.

Sara Baldassari, Paola Cirrincione, Giorgia Ailuno, Giuliana Drava, Silvia Arpicco, Gabriele Caviglioli

Open access · goldAbstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sara BaldassariDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
Paola CirrincioneDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
Giorgia AilunoDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
Giuliana DravaDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
Silvia ArpiccoDepartment of Drug Science and Technology, University of Torino, Via Giuria 9, 10125 Torino, Italy.
Gabriele CaviglioliDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
University of Genoa · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycarbophil (POL), a polyacrylic acid cross-linked with divinyl glycol, is widely used in semisolid and solid dosage forms. When undergoing a thermal treatment in the range 120-160 °C, POL shows interesting morphological modifications, related to changes in physical properties, such as swelling of the powder granules, or hardening and matrix formation if included in the composition of a tablet. Thermal analysis conducted on POL highlighted a thermal event (Z) that can be correlated both to the shrinking of the powder granules and to the matrix formation in compacted POL powder. Modulated differential scanning calorimetry (MDSC) allowed to distinguish, inside event Z, an irreversible process overlapping with a reversible glass transition, attributable to the volatilization of residual solvents identified, through a complex TGA-FTIR-GC-MS interface, as acetate esters used for the polymer production as very fine powder. A specific interaction between acetates and POL, capable of stabilizing the polymer chains in a given conformation, was highlighted. The molecular rearrangement of the POL chains, following the volatilization of the solvent-stabilizers, is therefore ascribable to a loss of energetic stability of this material, which justifies the shrinking phenomena in the granules of the powder and the matrix formation when POL is compacted.

Indexed as

Cross-linked polyacrylic polymerGlass transitionMatrix tabletShrinkingSolid dosage formsThermal treatment

Identifiers

PMID34661093
PMCPMC8503905
OpenAlexW3205216527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.